Navigation Links
2009 Lasker Awards recognize promise of stem cells -- global market could top $700 million

New Rochelle, NY, September 14, 2009The recipients of The 2009 Lasker Awards, announced today, represent the dramatic advances achieved in biotechnology research that have led to a revolutionary cancer treatment and the tremendous promise of stem cell therapy for regenerative medicine. Such advances portend a potential $700 million global market for new therapies within less than five years, according to Genetic Engineering & Biotechnology News (GEN,

The Albert Lasker Basic Medical Research Award for 2009 recognizes discoveries in the process that instructs specialized adult cells to form stem cells, and will be presented to Sir John Gurdon, DPhil, DSc, FRS, Emeritus Professor and Group Leader, Gurdon Institute of Cancer & Developmental Biology, University of Cambridge, and Shinya Yamanaka, MD, PhD, Institute for Integrated Cell-Material Sciences, Kyoto University.

The 2009 Lasker-DeBakey Clinical Medical Research Award honors outstanding therapeutic research on chronic myeloid leukemia, and will be given to Brian J. Druker, MD, Professor of Medicine and Director of the Leukemia Center, Oregon Health Sciences University, Nicholas B. Lydon, PhD, formerly of Novartis, and Charles L. Sawyers, MD, Head of the Laboratory in Human Oncology and Pathogenesis, Memorial Sloan-Kettering Cancer Center.

Providing insight and expert commentary on the awards in an article appearing today on the GEN website ( are prominent scientists Professor Sir Ian Wilmut, editor of the journal Cloning and Stem Cells (, and Graham Parker, PhD, editor of Stem Cells and Development ( Also providing authoritative perspectives are Maria Freire, PhD, president of the Lasker Foundation, Peter C. Johnson, MD, president and CEO of Scintellix and executive vice president and chief medical officer at Entegrion, and Linda Powers, co-founder and managing director of Toucan Capital, which manages a portfolio that includes 16 stem cell or regenerative medicine companies.

"The 2009 Lasker Awards for basic and clinical research underscore the enormous impact that scientific research and translational medicine will have on human health," said John Sterling, Editor in Chief of GEN. "In the areas of embryonic and adult stem cells, this international recognition of the implications for nuclear reprogramming techniques and the ability to produce stem cells capable of regenerating tissues and organs damaged by disease, trauma, or age, will ignite new research ventures and collaborative partnerships and spark investment across the life sciences sector."

"Both embryonic and adult stem cells offer enormous promise for new treatments and cures," said Mary Ann Liebert, president and CEO of Mary Ann Liebert, Inc. "It is urgent that any health care reform policy ensures coverage for stem cell therapies, gene therapies, tissue engineering, and other regenerative therapeutics and technologies," she said.


Contact: John Sterling
Mary Ann Liebert, Inc./Genetic Engineering News

Related biology news :

1. Anthony S. Fauci awarded Lasker Award for Public Service
2. MGH researcher Gary Ruvkun named a co-recipient of the Lasker Award
3. Gladstones Shinya Yamanaka wins Lasker Award
4. The American Society of Plant Biologists announces 2007 awards
5. Singapore National Science and Technology Awards
6. Homeland Security awards 2 grants to Rutgers for nuclear threat detection
7. NIH awards nearly $23M to University of Chicago for translational research
8. NIH awards researcher $1.5 million new innovator grant for fruit-fly studies of prion proteins
9. PETA awards $120,000 to Duluth Foundation for advancing non-animal tests
10. NIH awards UC $9 million grant to improve patient point-of-care technologies
11. NIST announces 56 new awards for innovative technology research and development
Post Your Comments:
(Date:11/2/2015)... MENLO PARK, Calif. , Nov. 2, 2015 /PRNewswire/ ... to $9 million to provide preclinical development services to ... Under the contract, SRI will provide scientific expertise, modern ... a wide variety of preclinical pharmacology and toxicology studies ... --> --> The PREVENT Cancer Drug ...
(Date:10/29/2015)... LA JOLLA, Calif. , Oct. 29, 2015 /PRNewswire-USNewswire/ ... released a new report titled, "DNA Synthesis and Biosecurity: ... how well the Department of Health and Human Services ... was issued in 2010. --> ... advances, but it also has the potential to pose ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, ... for U.S. distribution of its DNA library preparation ... and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq ... the preparation of NGS libraries for liquid biopsies--the ... diagnostic and prognostic applications in cancer and other ...
Breaking Biology News(10 mins):
(Date:12/1/2015)... 1, 2015  Symic, a clinical-stage biotherapeutics company developing ... (ECM), today announced that it has secured $25 million ... pipeline, including its lead candidates SB-030 and SB-061. The ... participation by all existing major investors, as well as ... capital raised by Symic to over $43 million since ...
(Date:12/1/2015)... Dallas, Texas (PRWEB) , ... December 01, 2015 ... ... its annual global meeting this month and Dr. J. Kyle Mathews ... worldwide.” This includes the new single site hysterectomy. , An experienced urogynecologist, founder ...
(Date:11/30/2015)... ... 2015 , ... Global Stem Cells Group Chile ... Central America and abroad for the first Iberoamerican Convention on Aesthetic Medicine, Cosmetology ... Testart will present and discuss new trends in anti-aging stem cell treatments, regenerative ...
(Date:11/30/2015)... ... ... Global Stem Cells Group announced the opening of a new core patient care ... in northern Chile. The facilities are part of GSCG’s expansion efforts in Latin America. ... stem cell medicine to patients from around the world. , The clinics will be headed ...
Breaking Biology Technology: